We are an emerging leader in optimizing the performance of small molecule drugs using our proprietary, controlled-release technologies. Our lead product, a unique, once-daily formulation of tramadol, is being commercially launched in key markets globally and we have a robust pipeline of follow-on products in both pre-clinical and clinical development.

We are on track to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize our own products.